increasing prevalence of coagulation disorders is driving the Heparin Market
Technavio analyzes that the Heparin Market is expected to grow at a CAGR of 7.22% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 3.34 billion.There are various factors that contribute to the growth of the market. The global Heparin market is experiencing significant growth due to the rising prevalence of coagulation disorders. Coagulation disorders, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), are increasingly common health concerns, particularly in populations with risk factors like aging, obesity, and immobility. Heparin, a natural anticoagulant, plays a crucial role in preventing and treating these conditions, thereby fueling market expansion.
In the healthcare industry, low-molecular-weight heparin (LMWH) is a crucial anticoagulant used for the prevention and treatment of various conditions, including chronic blood diseases, fungal infections, and counterfeit drugs. LMWH inhibits the coagulation cascade by activating antithrombin III, which in turn inhibits factor Xa and prevents the conversion of prothrombin to thrombin, thereby hindering the formation of fibrin from fibrinogen. This extended activity is achieved through the depolymerization of unfractionated heparin into shorter chains by chemical or enzymatic methods. By doing so, LMWH provides more reliable and efficient anticoagulation therapy compared to unfractionated heparin in managing conditions related to chronic diseases, noncommunicable diseases (NCDs), and cardiovascular diseases (CVD).
Know which region is leading the market growth by requesting a sample report
Heparin Market Segmentation
As per our research findings, here are some of the key competitors that are leading the industry
Find out what is trending in the market by accessing the free PDF report
The Heparin market caters to the demand for an injectable anticoagulant used in preventing and managing various blood clotting disorders, including venous thromboembolism from accidents and chronic diseases like diabetes and atrial fibrillation. Derived from animal sources, Unfractionated Heparin is used to prevent blood clots in veins and arteries, reducing the risk of pulmonary embolism and arterial thromboembolism. It is administered subcutaneously or intravenously and is essential for elderly demographics and those with a history of blood donation or anticoagulant therapy. Plasma-derived therapies (PDTs) serve as alternatives for those with allergies to animal-derived products. Heparin is crucial in managing blood clotting disorders related to accidents, chronic diseases, and conditions like atrial fibrillation.
The heparin market, identified as a segment of the expansive global pharmaceuticals industry within the healthcare sector, experienced significant growth in 2023, valued at USD1.495.51 billion. This market expansion is driven by the increasing global population aging, leading to a higher demand for injectable anticoagulants like heparin to prevent blood clotting in veins due to venous thromboembolism. The pharmaceuticals industry, a key component of the overall healthcare market, encompasses entities involved in research and development or production of various drug categories, including heparin, generic drugs, non-generic drugs, and veterinary drugs. The pharmaceuticals market's growth is further fueled by advancements in drug technology and the rising prevalence of chronic diseases.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
